Exec Chat: Medtronic Diabetes VP Talks Value-Based Health Care
Medtronic Diabetes exec Suzanne Winter talks with Medtech Insight about her business' approach to value-based health care, including recently inked agreements with insurers such as Aetna and United Healthcare.
You may also be interested in...
Medtronic and UnitedHealthcare have evidence that their year-old partnership is improving health outcomes in diabetes patients that require intensive insulin delivery. An analysis of more than 6,000 UnitedHealthcare members with diabetes who used Medtronic's MiniMed 630G and previous generation insulin pumps between July 2016 and July 2017 showed 27% fewer preventable hospital admissions compared to plan-participants who were using multiple daily injections of insulin.
The device-maker will be on the hook to provide rebates to the health insurer if its self-adjusting insulin pumps don't maintain patients in appropriate glucose ranges, under a newly inked agreement. Medtronic already has a similar arrangement with UnitedHealthcare.
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.